All News
Methotrexate Impairs COVID Vax Response
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Read ArticleTocilizumab Risk of Diverticulitis and GI Perforation
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA
Read ArticleNSAID Safety with COVID-19 Infection
NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Read ArticleRheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read ArticleRheumatic Patients Are at Risk for COVID Death
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
CARD8 SNP rs11672725 (OR 3) may be a Genetic Variant for AdultStill’s Disease. AOSD has unregulated NLR3 inflammasome activity. Study of 66 AOSD & 128 controls, showed AOSD to have low CARD8, higher caspase-1, IL-1β and IL-18; more systemic Sxs https://t.co/rpypR4cLfM
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Interestng overview/read on the Inflammasome - its history, clinical targeting and new inflammasome (NLRP3) inhibitors in development by pharma. https://t.co/DEdP09GZd7
Links:
Dr. John Cush RheumNow ( View Tweet)
French review of 41 TRAPS pts w/ amyloidosis AA. AA dx preceded TRAPS in 96% of cases, 47% needed renal replacement therapy and 14% died at 23 most F/U. 19 pts took biologics, 10 improved, 7 stabilized, 4 worsened. AA pts should be screened for TRAPS https://t.co/tONNSRCoOU
Links:
Dr. John Cush RheumNow ( View Tweet)
122 Adult onset Still's disease pts followed a median of 12 mos shows 21% with >=1 relapses. The cumulative relapse rate was 29% at 36 mos. Relapses increased w intensive Rx (OR 6.8) & MAS (OR 4.0)."Intensive" refers to steroids plus DMARDs - not biologics https://t.co/BRKi5sUQQZ
Links:
Dr. John Cush RheumNow ( View Tweet)


